Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Bacterial genotypic and patient risk factors for adverse outcomes in Escherichia coli bloodstream infections: a prospective molecular-epidemiological study

View ORCID ProfileElita Jauneikaite, View ORCID ProfileKate Honeyford, Oliver Blandy, View ORCID ProfileMia Mosavie, View ORCID ProfileMax Pearson, View ORCID ProfileFarzan A. Ramzan, Matthew J. Ellington, View ORCID ProfileJulian Parkhill, View ORCID ProfileCéire E Costelloe, Neil Woodford, View ORCID ProfileShiranee Sriskandan
doi: https://doi.org/10.1101/2021.06.18.21258557
Elita Jauneikaite
1NIHR Health Protection Research Unit for Healthcare Associated Infections and Antimicrobial Resistance, Department of Infectious Disease, Imperial College London, London, UK
2Department of Infectious Disease Epidemiology, School of Public Health, Imperial College London, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Elita Jauneikaite
Kate Honeyford
1NIHR Health Protection Research Unit for Healthcare Associated Infections and Antimicrobial Resistance, Department of Infectious Disease, Imperial College London, London, UK
3Global Digital Health Unit, Department of Primary Care and Public Health, School of Public Health, Imperial College London, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Kate Honeyford
Oliver Blandy
1NIHR Health Protection Research Unit for Healthcare Associated Infections and Antimicrobial Resistance, Department of Infectious Disease, Imperial College London, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mia Mosavie
1NIHR Health Protection Research Unit for Healthcare Associated Infections and Antimicrobial Resistance, Department of Infectious Disease, Imperial College London, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Mia Mosavie
Max Pearson
1NIHR Health Protection Research Unit for Healthcare Associated Infections and Antimicrobial Resistance, Department of Infectious Disease, Imperial College London, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Max Pearson
Farzan A. Ramzan
1NIHR Health Protection Research Unit for Healthcare Associated Infections and Antimicrobial Resistance, Department of Infectious Disease, Imperial College London, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Farzan A. Ramzan
Matthew J. Ellington
1NIHR Health Protection Research Unit for Healthcare Associated Infections and Antimicrobial Resistance, Department of Infectious Disease, Imperial College London, London, UK
4NIS Laboratories, National Infection Service, Public Health England, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Julian Parkhill
5Wellcome Sanger Institute, Hinxton, Cambridge, UK
6Department of Veterinary Medicine, University of Cambridge, Cambridge, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Julian Parkhill
Céire E Costelloe
3Global Digital Health Unit, Department of Primary Care and Public Health, School of Public Health, Imperial College London, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Céire E Costelloe
Neil Woodford
1NIHR Health Protection Research Unit for Healthcare Associated Infections and Antimicrobial Resistance, Department of Infectious Disease, Imperial College London, London, UK
4NIS Laboratories, National Infection Service, Public Health England, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shiranee Sriskandan
1NIHR Health Protection Research Unit for Healthcare Associated Infections and Antimicrobial Resistance, Department of Infectious Disease, Imperial College London, London, UK
7Medical Research Council Centre for Molecular Bacteriology & Infection, Imperial College London, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Shiranee Sriskandan
  • For correspondence: s.sriskandan@imperial.ac.uk
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Background Escherichia coli bloodstream infections have increased rapidly in the UK, for reasons that are unclear. The relevance of highly fit, or multi-drug resistant lineages such as ST131 to overall E. coli disease burden remains to be fully determined. We set out to characterise the prevalence of E. coli multi-locus sequence types (MLST) and determine if these were associated with adverse outcomes in an urban population of E. coli bacteraemia patients.

Methods We undertook whole genome sequencing of E. coli blood isolates from all patients with diagnosed E. coli bacteraemia in north-west London from July 2015 to August 2016 and assigned multi-locus sequence types to all isolates. Isolate sequence types were linked to routinely collected antimicrobial susceptibility, patient demographic, and clinical outcome data to explore relationships between the E. coli sequence types, patient factors, and outcomes.

Findings A total of 551 E. coli genomes were available for analysis. More than half of these cases were caused by four E. coli sequence types: ST131 (21%), ST73 (15%), ST69 (9%) and ST95 (8%). E. coli genotype ST131-C2 was associated with non-susceptibility to quinolones and third-generation cephalosporins, and also to amoxicillin, augmentin, gentamicin and trimethoprim. An association between the ST131-C2 lineage and longer length-of-stay was detected, although multivariable regression modelling did not demonstrate an association between E. coli sequence type and mortality. However, a number of unexpected associations were identified, including gentamicin non-susceptibility, ethnicity, and sex that might influence mortality and length-of-stay, requiring further research.

Interpretation Although E. coli sequence type was associated with antimicrobial non-susceptibility patterns and length-of-stay, we did not find that E. coli sequence type was associated with increased mortality. Where ST131 is prevalent, caution is required when pairing beta-lactam agents with gentamicin or using single agent aminoglycosides.

Funding UK NIHR HPRU, Wellcome Trust, Rosetrees Trust, Stoneygate Trust.

Evidence before this study E. coli is the leading cause of bacteraemia in adults, with consequent major impact on patient morbidity and mortality, as well as cost of care. Identification of microbial and patient factors that contribute to severity from E. coli bacteraemia could inform clinical guidelines and improve outcomes. We searched PubMed for articles published in English between 1st of Jan 1999 to 3rd of May 2021 using the following terms: (“Escherichia coli” OR “E. coli”) AND (“bacteraemia” OR “bloodstream infection”) AND (“genotype” OR “multi-locus sequence typing” OR “MLST”). We screened titles, abstracts, and bibliographies of relevant articles to identify reports that examine microbial factors that influence outcome. Previous studies have examined the association between a narrow range of E. coli lineages carrying specific antimicrobial resistance genes and prior antibiotic consumption, patient comorbidities, and mortality. Only two previous studies have examined the association of a wider range of E. coli sequence types (via MLST or whole genome sequencing) with clinical disease phenotype. We provide an integrated observational analysis of E. coli sequence types, patient demographic data, and disease outcomes.

Added value of this study We provide whole genome sequences from an un-biased collection of 551 E. coli strains causing consecutive bloodstream infections (BSI) in a one-year period in London. The study confirms ST131 to be the single leading BSI-causing genotype, albeit accounting for just 21% of infections. Only half of these were from the so-called multi-drug resistant ST131-C2 lineage however, suggesting factors other than antimicrobial resistance alone contribute to fitness of ST131, and other currently dominant lineages. The study provides a valuable resource to link genome sequence to antimicrobial resistance phenotypes and evaluates the contribution of both bacterial sequence type and patient factors to disease outcome. E. coli ST131 subclade C2 was associated with non-susceptibility to multiple antibiotics as well as a longer length-of-stay, underlining a value in sequence-type surveillance, but we did not detect an association with mortality. Multi-variate analysis unexpectedly identified ethnicity as a potential contributor to 90-day mortality, mandating further investigation, while microbial gentamicin resistance was also linked to adverse outcome.

Implications of all available evidence E. coli bloodstream infections continue to rise in the UK, despite implemented strategies aimed at reducing E. coli invasive infections and antimicrobial resistance. Certain E. coli lineages are more likely to be multidrug-resistant or associated with specific infection types, however a more detailed understanding of changes in these pathogenic lineages over time in vulnerable populations is needed. Although multi-drug resistant lineages such as ST131-C2 contribute to prolonged length-of-stay, factors other than E. coli genotype may have a greater role to play in final outcome. While co-morbidities play a major role in mortality from E. coli bacteraemia, other demographic factors require attention. A more comprehensive analysis of associations between E. coli genotype, patient factors, antimicrobial resistance phenotypes and clinical outcomes could inform prescribing guidelines for both urinary tract and invasive E. coli infections. Such information will further serve as a potential driver for developing and implementing lineage-specific E. coli vaccines in the future.

Competing Interest Statement

JP is a paid consultant to Next Gen Diagnostics Llc. MJE and NW are members of PHEs Antimicrobial Resistance and Healthcare Associated Infections Reference Unit, which has received financial support for conference attendance, lectures, research projects, or contracted evaluations from numerous sources, including Accelerate Diagnostics, Achaogen Inc, Allecra Therapeutics, Amplex, AstraZeneca UK Ltd, AusDiagnostics, Basilea Pharmaceutica, Becton Dickinson Diagnostics, bioMerieux, Bio-Rad Laboratories, British Society for Antimicrobial Chemotherapy, Cepheid, Check-Points B.V., Cubist Pharmaceuticals, Department of Health, Enigma Diagnostics, the European Centre for Disease Prevention and Control, Food Standards Agency, GenePOC, GlaxoSmithKline Services Ltd, Helperby Therapeutics, Henry Stewart Talks, International Health Management Associates Ltd, Innovate UK, Kalidex Pharmaceuticals, Melinta Therapeutics, Merck Sharpe and Dohme, Meiji Seika Pharma Co Ltd, Mobidiag, Momentum Biosciences Ltd, Neem Biotech, NIHR, Nordic Pharma Ltd, Norgine Pharmaceuticals, Paratek, Rabiotics Rx, Rempex Pharmaceuticals Ltd, Roche, Rokitan Ltd, Smith and Nephew UK Ltd, Shionogi and Co Ltd, Tetraphase Pharmaceuticals, Trius Therapeutics, VenatoRx Pharmaceuticals, Wockhardt Ltd, and the World Health Organization. All other authors have no competing interest to declare.

Funding Statement

The research was funded by the National Institute for Health Research Health Protection Research Unit (NIHR HPRU) in Healthcare Associated Infections and Antimicrobial Resistance at Imperial College London in partnership with Public Health England (HPRU-2012-10047). This report is independent research funded by the National Institute for Health Research. The views expressed in this publication are those of the author(s) and not necessarily those of the NHS, the National Institute for Health Research, the Department of Health and Social Care or Public Health England. NW and MJE were also supported by PHE and the Joint Programming Initiative on Antimicrobial Resistance (JPIAMR) and the Medical Research Council (MRC) as part of the ST131TS Consortium under grant code MR/R002843/1. The funding sources had no role in study design, data collection, analysis, or decision to submit the manuscript for publication. SS acknowledges the support of the NIHR Imperial Biomedical Research Centre (BRC). EJ is a Rosetrees/Stoneygate 2017 Imperial College Research Fellow (M683). CEC is supported by a personal NIHR Career Development Fellowship (NIHR-2016-090-015). Imperial College London is grateful for the support from the North West London NIHR Applied Research Collaboration. The funders had no role in study design or writing.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The collection of microbial isolates and linkage to routinely obtained healthcare data prior to anonymisation was approved by an NHS Research Ethics Committee (West London Research Ethics Committee, formerly Hammersmith and Queen Charlotte’s & Chelsea Research Ethics Committee). Ethics approval reference number 06/Q0406/20.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

Whole genome sequencing reads were deposited in European Nucleotide Archive under the BioProject accession PRJEB20357, individual isolate accession numbers are shown in Table S5.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted June 18, 2021.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Bacterial genotypic and patient risk factors for adverse outcomes in Escherichia coli bloodstream infections: a prospective molecular-epidemiological study
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Bacterial genotypic and patient risk factors for adverse outcomes in Escherichia coli bloodstream infections: a prospective molecular-epidemiological study
Elita Jauneikaite, Kate Honeyford, Oliver Blandy, Mia Mosavie, Max Pearson, Farzan A. Ramzan, Matthew J. Ellington, Julian Parkhill, Céire E Costelloe, Neil Woodford, Shiranee Sriskandan
medRxiv 2021.06.18.21258557; doi: https://doi.org/10.1101/2021.06.18.21258557
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Bacterial genotypic and patient risk factors for adverse outcomes in Escherichia coli bloodstream infections: a prospective molecular-epidemiological study
Elita Jauneikaite, Kate Honeyford, Oliver Blandy, Mia Mosavie, Max Pearson, Farzan A. Ramzan, Matthew J. Ellington, Julian Parkhill, Céire E Costelloe, Neil Woodford, Shiranee Sriskandan
medRxiv 2021.06.18.21258557; doi: https://doi.org/10.1101/2021.06.18.21258557

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (216)
  • Allergy and Immunology (495)
  • Anesthesia (106)
  • Cardiovascular Medicine (1099)
  • Dentistry and Oral Medicine (196)
  • Dermatology (141)
  • Emergency Medicine (274)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (502)
  • Epidemiology (9781)
  • Forensic Medicine (5)
  • Gastroenterology (481)
  • Genetic and Genomic Medicine (2317)
  • Geriatric Medicine (223)
  • Health Economics (462)
  • Health Informatics (1563)
  • Health Policy (737)
  • Health Systems and Quality Improvement (606)
  • Hematology (238)
  • HIV/AIDS (506)
  • Infectious Diseases (except HIV/AIDS) (11656)
  • Intensive Care and Critical Care Medicine (617)
  • Medical Education (239)
  • Medical Ethics (67)
  • Nephrology (258)
  • Neurology (2147)
  • Nursing (134)
  • Nutrition (338)
  • Obstetrics and Gynecology (427)
  • Occupational and Environmental Health (518)
  • Oncology (1183)
  • Ophthalmology (365)
  • Orthopedics (128)
  • Otolaryngology (220)
  • Pain Medicine (147)
  • Palliative Medicine (50)
  • Pathology (313)
  • Pediatrics (698)
  • Pharmacology and Therapeutics (302)
  • Primary Care Research (267)
  • Psychiatry and Clinical Psychology (2187)
  • Public and Global Health (4672)
  • Radiology and Imaging (781)
  • Rehabilitation Medicine and Physical Therapy (457)
  • Respiratory Medicine (624)
  • Rheumatology (274)
  • Sexual and Reproductive Health (226)
  • Sports Medicine (210)
  • Surgery (252)
  • Toxicology (43)
  • Transplantation (120)
  • Urology (94)